Alzamend Neuro, Inc. — Director's Dealing 2021

Jun 15, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-06-14

Reporting Person: Horne William B. (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$0.004	2026-04-29	Common Stock (2500000)		Direct
Stock Options (Right to Buy)	$1.50	2029-11-25	Common Stock (250000)		Direct
Stock Options (Right to Buy)	$1.50	2029-11-25	Common Stock (250000)		Direct

Footnotes

F1: Mr. Horne was granted stock options to purchase 2,500,000 shares of Common Stock, which options are exercisable at an exercise price of $0.004 and are currently vested and exercisable.

F2: Mr. Horne was granted stock options to purchase 250,000 shares of Common Stock, which options are exercisable at an exercise price of $1.50 per share, and vest ratably over thirty-six (36) months beginning on the date of grant. Of these options, 125,000 shares of Common Stock are vested and exercisable.

F3: Mr. Horne was granted performance-based stock options to purchase 250,000 shares of Common Stock, which options are exercisable for a period of ten (10) years at an exercise price of $1.50 per share. Of these options, no shares of Common Stock are vested and exercisable.